Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a complex autoimmune disease caused by dysregulated response to not fully recognized antigens. Some association between CIDP and inflammatory bowel disease (IBD) has been reported, but the exact pathophysiological links of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Magdalena Koszewicz, Agata Mulak, Edyta Dziadkowiak, Sławomir Budrewicz
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	chronic inflammatory demyelinating polyneuropathy intestinal inflammation fecal calprotectin gut immune system gut microbiota Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/bb9ea6807f5b4880a217c34bde1785f5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb9ea6807f5b4880a217c34bde1785f5
record_format	dspace
spelling	oai:doaj.org-article:bb9ea6807f5b4880a217c34bde1785f52021-11-12T05:37:32ZIs Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study1662-516110.3389/fnhum.2021.733070https://doaj.org/article/bb9ea6807f5b4880a217c34bde1785f52021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fnhum.2021.733070/fullhttps://doaj.org/toc/1662-5161Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a complex autoimmune disease caused by dysregulated response to not fully recognized antigens. Some association between CIDP and inflammatory bowel disease (IBD) has been reported, but the exact pathophysiological links of these disorders are not well understood.Aim of the Study: To evaluate fecal calprotectin as a biomarker of gut inflammation in CIDP patients without IBD.Methods: Fifteen patients with CIDP and 15 healthy controls were included in the study. The CIDP diagnosis was based on the EFNS/PNS criteria. The occurrence of bowel symptoms was assessed based on a questionnaire. The quantitative evaluation of fecal calprotectin level was performed by the ELISA test.Results: The fecal calprotectin level (μg/g) expressed as median along with the lower and upper quartiles [25Q–75Q] was significantly higher in CIDP patients compared to the controls: 26.6 [17.5–109.0] vs 15.6 [7.1–24.1], p = 0.0066. Abnormal fecal calprotectin level (>50 μg/g) was found in 33% of all CIDP patients and in none of the control subjects. The patients with abnormal fecal calprotectin level did not differ from the rest of the study group regarding the neurological status. The most common bowel symptoms reported by CIDP patients included constipation (33%), feeling of incomplete evacuation (33%), bloating (27%), and alternating bowel movement pattern (27%).Conclusion: In one-third of CIDP patients the signs of gut immune system activation have been observed. This finding may be associated with CIDP pathogenesis and induction of autoimmune response as well as concomitant dysautonomia with gastrointestinal symptoms.Magdalena KoszewiczAgata MulakEdyta DziadkowiakSławomir BudrewiczFrontiers Media S.A.articlechronic inflammatory demyelinating polyneuropathyintestinal inflammationfecal calprotectingut immune systemgut microbiotaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENFrontiers in Human Neuroscience, Vol 15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic inflammatory demyelinating polyneuropathy intestinal inflammation fecal calprotectin gut immune system gut microbiota Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	chronic inflammatory demyelinating polyneuropathy intestinal inflammation fecal calprotectin gut immune system gut microbiota Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Magdalena Koszewicz Agata Mulak Edyta Dziadkowiak Sławomir Budrewicz Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
description	Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a complex autoimmune disease caused by dysregulated response to not fully recognized antigens. Some association between CIDP and inflammatory bowel disease (IBD) has been reported, but the exact pathophysiological links of these disorders are not well understood.Aim of the Study: To evaluate fecal calprotectin as a biomarker of gut inflammation in CIDP patients without IBD.Methods: Fifteen patients with CIDP and 15 healthy controls were included in the study. The CIDP diagnosis was based on the EFNS/PNS criteria. The occurrence of bowel symptoms was assessed based on a questionnaire. The quantitative evaluation of fecal calprotectin level was performed by the ELISA test.Results: The fecal calprotectin level (μg/g) expressed as median along with the lower and upper quartiles [25Q–75Q] was significantly higher in CIDP patients compared to the controls: 26.6 [17.5–109.0] vs 15.6 [7.1–24.1], p = 0.0066. Abnormal fecal calprotectin level (>50 μg/g) was found in 33% of all CIDP patients and in none of the control subjects. The patients with abnormal fecal calprotectin level did not differ from the rest of the study group regarding the neurological status. The most common bowel symptoms reported by CIDP patients included constipation (33%), feeling of incomplete evacuation (33%), bloating (27%), and alternating bowel movement pattern (27%).Conclusion: In one-third of CIDP patients the signs of gut immune system activation have been observed. This finding may be associated with CIDP pathogenesis and induction of autoimmune response as well as concomitant dysautonomia with gastrointestinal symptoms.
format	article
author	Magdalena Koszewicz Agata Mulak Edyta Dziadkowiak Sławomir Budrewicz
author_facet	Magdalena Koszewicz Agata Mulak Edyta Dziadkowiak Sławomir Budrewicz
author_sort	Magdalena Koszewicz
title	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
title_short	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
title_full	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
title_fullStr	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
title_full_unstemmed	Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study
title_sort	is fecal calprotectin an applicable biomarker of gut immune system activation in chronic inflammatory demyelinating polyneuropathy? – a pilot study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/bb9ea6807f5b4880a217c34bde1785f5
work_keys_str_mv	AT magdalenakoszewicz isfecalcalprotectinanapplicablebiomarkerofgutimmunesystemactivationinchronicinflammatorydemyelinatingpolyneuropathyapilotstudy AT agatamulak isfecalcalprotectinanapplicablebiomarkerofgutimmunesystemactivationinchronicinflammatorydemyelinatingpolyneuropathyapilotstudy AT edytadziadkowiak isfecalcalprotectinanapplicablebiomarkerofgutimmunesystemactivationinchronicinflammatorydemyelinatingpolyneuropathyapilotstudy AT sławomirbudrewicz isfecalcalprotectinanapplicablebiomarkerofgutimmunesystemactivationinchronicinflammatorydemyelinatingpolyneuropathyapilotstudy
_version_	1718431194408812544

Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? – A Pilot Study

Ejemplares similares